Long COVID’s Dopamine Crash Exposed

Healthcare professional uses tablet with medical holograms — Photo: metamorworks / Shutterstock

Brain scans now tie long COVID’s fog and fatigue to a measurable drop in dopamine signaling.

Story Snapshot

Positron emission scans found 16% to 20% lower VMAT2 in long COVID patients’ striatum.
Lower dopamine terminal marker linked to apathy, slower movement, and memory issues.
The cohort had mild or moderate initial infections, broadening relevance beyond severe cases.
VMAT2 is a recognized marker of dopamine neuron terminal integrity in humans.

Brain Imaging Finds A Clear Dopamine Signal In Long COVID

Researchers scanned 24 adults with long COVID and 24 healthy controls. The team measured vesicular monoamine transporter 2, a protein in dopamine-releasing nerve terminals, using positron emission tomography. Binding was lower across three key parts of the striatum. The reduction ranged from about 16% in dorsal putamen to about 20% in ventral striatum, with dorsal caudate near 17% lower. These regions drive motivation, movement, and certain thinking tasks.

The study tied these brain changes to symptoms that define long COVID for many patients. Lower ventral striatum signal aligned with greater apathy. Reduced putamen signal tracked with slower movement. Lower caudate signal lined up with worse memory performance. The pattern fits what many describe: a flat battery, heavy limbs, and a mind that misfires at random moments. Reporters noted participants started with mild or moderate infections, not severe hospital stays.

Why VMAT2 Matters More Than A Vague “Brain Abnormality”

Vesicular monoamine transporter 2 is not a guesswork marker. Nuclear medicine uses it to index the integrity of monoaminergic terminals, especially dopamine. Decades of research in Parkinson’s disease link lower VMAT2 binding with loss of dopamine nerve terminals. That gives this result weight beyond mood scales or fuzzy functional scans. It offers a concrete biological footprint that matches the real-world problems patients face day to day.

The striatum is the hub where motivation meets movement. When dopamine terminals thin out there, the body slows and the mind stalls. Apathy is not laziness; it is a signal problem. Slower finger taps and gait can follow. Memory can slip when the caudate is underfueled. The new data map symptom to structure in a way that makes sense. That coherence, more than any single number, is what grabs attention in clinics and living rooms.

What The Numbers Say—And What They Do Not

The reduction is not a blip. Multiple outlets reported the same effect size, the same regions, and the same direction of change. The summary reads like a short checklist: ventral striatum down about 20%, dorsal putamen down about 16%, dorsal caudate down about 17%—and stronger apathy, slower movement, and worse memory that align with each region’s job. A brief caveat still applies: the imaging shows fewer working terminals or lower marker expression; it does not prove neuron death.

Researchers have found evidence that long COVID may damage dopamine releasing neurons in the brain, potentially explaining persistent fatigue, low motivation, slowed movement, and memory difficulties. The discovery could lead to new treatments that target https://t.co/YTeLtXkt5q

— Michael W. Deem (@Michael_W_Deem) September 22, 2026

Common sense points to the practical next steps. Larger groups can test whether this pattern marks a subtype or the wider long COVID population. Repeat scans over time can tell if the signal tracks recovery or decline. Lab work can pair scans with signs of inflammation or immune activity. These moves would show whether the dopamine hit is cause, effect, or both. For families and doctors, the core advance stands: the fog and fatigue now have a visible, targetable trail.